Apollo Hospitals Enterprise Ltd has received approval from NCLT for a restructuring plan that unites Apollo Healthco, Keimed Pvt Ltd, and Apollo Healthtech. The goal is to optimize operations, bolster sector-specific efficiencies, and expand business potential for all parties involved.

Investment firm Citi is optimistic about Apollo Hospitals, setting a target price of Rs. 9,600. This price point indicates a potential increase of 28% from the current level, suggesting a strong investment opportunity due to factors such as ongoing hospital expansion, the nearing breakeven of their digital platform, and HealthCo's promising 17-18% CAGR contributing to profitability.

Apollo Healthco has fully taken over Apollo Consumer Products for approximately INR 9L, making the latter a completely owned subsidiary. This move strengthens Apollo Healthco's reach in the Fast-Moving Consumer Goods (FMCG) sector.

Apollo Hospitals reports a steady patient demand amidst increasing operational costs within the Indian healthcare sector. Suneeta Reddy emphasizes the potential for growth in the healthcare industry, despite encountering escalating expenses.

Apollo Hospitals boasts a higher Price/Earnings ratio (P/E) than the industry at 59.8, suggesting a strong valuation. Despite short-term fluctuations, its long-term prospects stay positive due to its status as a Nifty 50 component.

Apollo Hospitals experienced a significant block trade on the NSE, selling around 32,157 shares at a price of INR 7,435. The total transaction amounted to approximately INR 23.91 crore.